Discover Insmed's innovative therapies targeting rare diseases, with approvals like Brinsupri boosting potential.

We came across a bullish thesis on MoonLake Immunotherapeutics on Valueinvestorsclub.com by skimmer610. In this article, we ...

Incyte Corporation (($CC:INCY.CUR)) announced an update on their ongoing clinical study. Study Overview: Incyte Corporation is conducting a Phase ...

Glucagon-like peptide-1 (GLP-1) receptor agonists show promise in reducing hidradenitis suppurativa severity and pain, especially in patients with obesity.

Panelists discuss the critical importance of early biologic therapy initiation in hidradenitis suppurativa to prevent irreversible tissue damage, reduce disease burden, and overcome socioeconomic and ...

Avalo Therapeutics (NASDAQ:AVTX) stock rises as Cantor Fitzgerald launches coverage with an Overweight rating, highlighting its lead asset, AVTX-009. Read more here.

The study also noted a 15% drop in substance misuse and showed benefit for patients who were taking stimulant medications rather than nonstimulants. Plus: developing new painkillers; how semaglutide ...

GLP-1 RA therapy reduces hidradenitis suppurativa severity, flares, symptoms, and BMI in patients with hidradenitis ...

The dermatology team at Zulekha Hospital is trained in the latest biological therapies ...

In the second quarter of 2025, Zura Bio initiated TibuSHIELD, a global Phase 2 clinical study evaluating tibulizumab in adults with moderate to severe HS. A topline data readout is anticipated in the ...

In this retrospective study, patients who started a GLP-1 agonist experienced significant declines in hidradenitis ...